Generic Medicine Info
Indications and Dosage
Dry eye
Adult: As 3% diquafosol sodium solution: Instill 1 drop into the affected eye(s) 6 times daily.
Adverse Reactions
Eye disorders: Eye irritation, eye discharge, conjunctival hyperaemia, eye pain, eye itching, foreign body sensation in eyes, ocular discomfort, increased lacrimation, blepharitis, hyposphagma, photophobia, blurred vision, corneal epithelium disorder (e.g. keratitis superficial, corneal erosion), conjunctivitis.
Patient Counseling Information
This drug may cause blurred vision, if affected, do not drive or operate machinery. Remove contact lenses prior to administration and reinsert after 15 minutes.
Mechanism of Action: Diquafosol acts on the P2Y2 receptors on the conjunctival epithelium and goblet cell membranes thereby increasing intracellular Ca ion concentration promoting water and mucin secretion.
Metabolism: Rapidly metabolised to uridine-5’-monophosphate, uridine and uracil.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Diquafosol, CID=148197, https://pubchem.ncbi.nlm.nih.gov/compound/Diquafosol (accessed on Jan. 21, 2020)

Store below 30°C.
MIMS Class
Ophthalmic Lubricants
Mun Y, Kwon JW, Oh JY. Therapeutic Effects of 3% Diquafosol Ophthalmic Solution in Patients with Short Tear Film Break-up Time-type Dry Eye Disease. BMC Ophthalmology. 2018;18:237. doi: 10.1186/s12886-018-0910-3. Accessed 18/10/2019

Nam K, Kim HJ, Yoo A. Efficacy and safety of topical 3% diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials. Ophthalmic Res. 2019 Jan;61(4):188-198. doi: 10.1159/000492896. Accessed 18/10/2019. PMID: 30654362

Buckingham R (ed). Diquafosol Tetrasodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/10/2019.

Diquas 3% Solution (Santen Pharma Malaysia Sdn. Bhd.). MIMS Malaysia. http://www.mims.com/malaysia. Accessed 18/10/2019.

Diquas 3% Solution (Santen Philippines Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 18/10/2019.

Disclaimer: This information is independently developed by MIMS based on Diquafosol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
  • Diquas
  • Diquas-S
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in